WHO Expert Committee on Selection and Use of Essential Medicines - WHO Technical Report Series, No. 850, Annex 3 (Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Products) - Sixth Report
(1995; 36 pages) [French] [Spanish] Voir le document au format PDF
Table des matières
Afficher le documentINTRODUCTION
Afficher le documentGLOSSARY
Fermer ce répertoire1. PROVISIONS AND PREREQUISITES FOR A CLINICAL TRIAL
Afficher le document1.1 Justification for the trial
Afficher le document1.2 Ethical principles
Afficher le document1.3 Supporting data for the investigational product
Afficher le document1.4 Investigator and site(s) of investigation
Afficher le document1.5 Regulatory requirements
Afficher le document2. THE PROTOCOL
Ouvrir ce répertoire et afficher son contenu3. PROTECTION OF TRIAL SUBJECTS
Ouvrir ce répertoire et afficher son contenu4. RESPONSIBILITIES OF THE INVESTIGATOR
Ouvrir ce répertoire et afficher son contenu5. RESPONSIBILITIES OF THE SPONSOR
Ouvrir ce répertoire et afficher son contenu6. RESPONSIBILITIES OF THE MONITOR
Ouvrir ce répertoire et afficher son contenu7. MONITORING OF SAFETY
Ouvrir ce répertoire et afficher son contenu8. RECORD KEEPING AND HANDLING OF DATA
Ouvrir ce répertoire et afficher son contenu9. STATISTICS AND CALCULATIONS
Ouvrir ce répertoire et afficher son contenu10. HANDLING OF AND ACCOUNTABILITY FOR PHARMACEUTICAL PRODUCTS
Ouvrir ce répertoire et afficher son contenu11. ROLE OF THE DRUG REGULATORY AUTHORITY
Afficher le document12. QUALITY ASSURANCE FOR THE CONDUCT OF A CLINICAL TRIAL
Afficher le document13. CONSIDERATIONS FOR MULTICENTRE TRIALS
Afficher le documentREFERENCES
Afficher le documentAPPENDIX 1: World Medical Association’s Declaration of Helsinki1
Afficher le documentAPPENDIX 2: Model list of items to be contained in a clinical trial protocol
 

1.4 Investigator and site(s) of investigation

Each investigator should have appropriate expertise, qualifications and competence to undertake a proposed study. Prior to the trial, the investigator(s) and the sponsor should establish an agreement on the protocol, standard operating procedures (SOP), the monitoring, and auditing of the trial, and the allocation of trial-related responsibilities. The trial site should be adequate to enable the trial to be conducted safely and efficiently (see chapter 4.7).

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013